Bayer to accelerate adoption of Aspivix’s medical device

An Intrauterine Contraceptive Device (IUD) is considered the most cost-effective birth control method available today. However, 18% of women avoid an IUD due to the fear of pain that about 90% of the women experience during the procedure using the traditional cervical tenaculum. Addressing this major challenge, Aspivix developed Carevix, an innovative, suction cervical stabilizer designed as a modern and gentler alternative to a cervical tenaculum.  

By leveraging suction technology to gently stabilize the cervix, Carevix delivers cervical engagement without the need to perforate the tissue. A semicircular, anatomical pad is applied onto the delicate tissue during gynecological procedures, reducing significantly trauma associated with pain and bleeding. 

The medtech startup now announced a partnership with Bayer (Switzerland) AG in Switzerland, a globally recognized leader in women’s health solutions and one of the world’s top producers of IUDs. Bayer (Schweiz) AG will use their marketing and digital outreach resources to expand the reach to all gynecologists in Switzerland and accelerate the availability of a gentle contraceptive solution provided by both Bayer and Aspivix. 

Bayer will facilitate the access of Carevix to Bayer’s customers and physicians in Switzerland through educational content on both platforms (MyAspivix.com and GynPortal.com from Bayer), and to convert non-intrauterine system (IUS) users because of pain. This will be achieved through training the new generation of OBGYN at hospitals and practices, joint presence at conferences, such as SGGG, regional and local workshops. Moreover, the collaboration will create new avenues to generate more clinical evidence that pain and bleeding can be reduced in IUDs placement with the companies’ combined solution. 

Aspivix CEO, Mathieu Horras, highlighted the company's dedication to improving women's healthcare. “ASPIVIX is excited to enter this partnership with Bayer (Schweiz) AG that truly emphasize the goal of empowering women to select the best contraceptive solution without worrying about potential pain and bleeding. The thorough research and clinical data behind Carevix guarantee a notable decrease in pain and bleeding, enhancing the experience of IUD adoption and placement, as well as various other gynecological procedures for millions of women.” 

Bayer Switzerland Women’s Healthcare lead, Marco Gierten, shares “As a globally trusted brand, Bayer remains committed to advancing solutions that provide significant benefits to patients.” 

(Press release/SR/RAN)